# A novel anti-mouse CXCR1 monoclonal antibody, Cx1Mab-8, demonstrates nanomolar affinity in flow cytometry

## TL;DR

A new monoclonal antibody, Cx1Mab-8, was developed to detect mouse CXCR1 with high affinity, potentially aiding tumor immunotherapy research.

## Contribution

Development of a novel anti-mouse CXCR1 monoclonal antibody with nanomolar affinity for flow cytometry.

## Key findings

- Cx1Mab-8 has a dissociation constant of 4.1 × 10−10 M for CHO/mCXCR1 and 1.5 × 10−9 M for LN229/mCXCR1.
- Cx1Mab-8 recognizes mCXCR1-overexpressed cell lines by flow cytometry with high affinity.
- Cx1Mab-8 could support preclinical studies in tumor immunotherapy.

## Abstract

CXC chemokine receptor 1 (CXCR1) is an important regulator for neutrophil granulocyte activation through binding to the ligand interleukin-8 (IL-8). Upon binding to IL-8, CXCR1 activates downstream signaling, critical for innate and adaptive immune responses. The IL-8-CXCR1 axis also plays an important role in tumor progression, especially in the tumor microenvironment. CXCR1 antagonists or anti-IL-8 monoclonal antibodies (mAbs) have been developed and evaluated in clinical trials for inflammatory diseases and tumors. In this study, we developed novel mAbs for mouse CXCR1 (mCXCR1) using the N-terminal peptide immunization. Among the established anti-mCXCR1 mAbs, Cx1Mab-8 (rat IgG2b, kappa) recognized mCXCR1-overexpressed Chinese hamster ovary-K1 (CHO/mCXCR1) and mCXCR1-overexpressed LN229 (LN229/mCXCR1) by flow cytometry. The dissociation constant (KD) values of Cx1Mab-8 for CHO/mCXCR1 and LN229/mCXCR1 were determined as 4.1 × 10−10 M and 1.5 × 10−9 M, respectively. These results indicated that Cx1Mab-8 is useful for detecting mCXCR1 by flow cytometry with high affinity and could contribute to obtaining the proof of concept in preclinical studies.

•A novel anti-mouse CXCR1 monoclonal antibody, Cx1Mab-8 were developed by the N-terminal peptide immunization.•Cx1Mab-8 is useful for detecting mCXCR1 by flow cytometry with high affinity.•Cx1Mab-8 could contribute to the preclinical studies for tumor immunotherapy.

A novel anti-mouse CXCR1 monoclonal antibody, Cx1Mab-8 were developed by the N-terminal peptide immunization.

Cx1Mab-8 is useful for detecting mCXCR1 by flow cytometry with high affinity.

Cx1Mab-8 could contribute to the preclinical studies for tumor immunotherapy.